Dr. Rachel Tate uptoTate
3 years 10 months ago
Avacopan's efficacy and safety profiles support use in AAV in Abs 1077 #ACR22 @RheumNow https://t.co/Zp05ofTgFP https://t.co/zA2sIEfYCS
Dr. John Cush RheumNow
3 years 10 months ago
Join us for our daily topic panels--we'll be live on Twitter, LinkedIn, FB and YouTube OR sign up directly below. #ACR22
https://t.co/Oql4iv6RyO https://t.co/S4t7ucliUF
While COVID vaccination and subsequent booster remain the cornerstone, pre-exposure prophylaxis such as Evusheld (tixagevimab and cilgavimab) has been approved by FDA in December 2021 and EMA in March 2022 for people immunocompromised either due to a medical condition or receiving treatment with immunosuppressants and may not mount an adequate immune response to COVID vaccination. How does this therapy fare in RMD patients?
Dr. John Cush RheumNow
3 years 10 months ago
Much gusto for GUSTO: Efficacy of Tocilizumab Monotherapy for GCA
Dr. Richard Conway discusses abstract 0470 - being presented at the #ACR22 meeting.
https://t.co/btztbYWjq1 https://t.co/hrpZhIRLKO
Eric Dein ericdeinmd
3 years 10 months ago
Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE
Higher copays associated w/:
💊39% lower odds of HCQ adherence
💊56% lower AZA adherence
💊32% lower MMF adherence
Need better $$ and transparency into costs. Screen for determinants of health affecting affordability!
@Rheumnow https://t.co/1NdBb3GLzL
Dr. Rachel Tate uptoTate
3 years 10 months ago
Abs 0829 at #ACR22 finds AOSD more commonly affects caucasian females. Also notes abnormal labs include elevated inflammatory markers, leukocytosis, and anemia. @RheumNow https://t.co/1Nr8C5dX3G
sheila RHEUMarampa
3 years 10 months ago
There's a lot of Scleroderma-like fibrosing skin disorders!
#ACR22 @RheumNow #RheumTwitter @rheumarhyme https://t.co/W1AEtfeKZc
Dr. Rachel Tate uptoTate
3 years 10 months ago
Serum AMH reduced in adolescents w/ rheumatic disease compared to menstrual-age matched, healthy controls. UCTD and SLE higher disease activity assoc'd w/ dec AMH levels, suggesting dz activity and dz may affect ovarian reserve. Abs 0942 #ACR22 @RheumNow https://t.co/xSZ85ipFSD https://t.co/tsaWBdrQcb
Mike Putman EBRheum
3 years 10 months ago
Excllent plenary, medication copay modifies treatment adherence in SLE
>$10 copay reduced adherence for HCQ (39%), AZA (56%), MMF (32%)
Easy to imagine that all our innovation cannot overcome access & barriers
Should be priority to fix
#ACR22 @RheumNow #ACRBest Abstr#1115 https://t.co/BPfr9mCVgy
Patricia Harkins DrTrishHarkins
3 years 10 months ago
Congenital ❤️ Block in Ro/La pregnancies
Abst#0957
👉1st echo @ mean 20wk
👉CHB 3/47- all on 1st echo
👉 1 reversed 3rd ➡️ 1st AVB post dexamethasone
🔥Key messages🔥
🤰serial echo should start @ 16-18wk gestation
👶 early detection ⬆️ outcomes
#ACR22 @RheumNow
Dr. Rachel Tate uptoTate
3 years 10 months ago
Combined estrogen-progestin contraception in SLE patients with positive aPL conferred an increased risk of thrombosis relative to progestin-only contraception. Abs 0943 #ACR22 @RheumNow https://t.co/B2Wmhlz6at https://t.co/YlvqoYY8FN
sheila RHEUMarampa
3 years 10 months ago
🖊️Eosinophilic fasciitis is not assoc. w/ RP
🖊️On biopsy, extends to SC fat and fascia
🖊️CS are 1st line tx; remission is the rule but takes a while so SLOWLY taper steroids
#ACR22 @Rheumnow #RheumTwitter https://t.co/Z26Gim9JUW
Dr. Rachel Tate uptoTate
3 years 10 months ago
Use of pregnancy-compatible medication and control of disease activity with lower glucocorticoid doses in PM/DM pregnancies may be important to achieve good pregnancy outcomes. Abs 0952 #ACR22 @RheumNow https://t.co/LMfebb4GE1 https://t.co/0gYG245BXV
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 10 months ago
#ACR22 Plenary II Abstr#1114 Access to therapy/Cost need to be improved since high copays (=> 10USD per month) affects adherence to treatment (HCQ, AZA, MMF but not MTX) in #lupus @RheumNow https://t.co/WnwIhpqDxL
